| Gene name: | MAPK8 |
| Aging type: | Prevent |
| Aging characteristic: |
| Tissue type: | -- |
| Cell name: | MCF-7 |
| Gene ID: | 5599 |
| Category: | protein coding |
| Phenotype: | Lung cancer |
| Experimental category: | L |
| PMID: | 19855432 |
| Experiment: | Cell morphological analysis//SA-β-gal activity assay//Flow cytometry |
| Description: | Cells treated with the JNK inhibitor,SP600125, showed senescence-specific large and flat cellular morphology and stained positively for SA-β-Gal activity.Positive SA-β-Gal activity gradually increased up to 7 days after SP600125 treatment.Analysis of cell cycle distribution revealed that only SP600125-treated cells were arrested in the G2/M phase and that the number of aneuploid cells (>4N) also increased. |
| Regulatory pathway: | BCL-2-ROS-DDR |
| R-AG-Pathway: | Activation |
| Official symbol(s): | BCL2 |
| Pathway experiment: | Colony formation assay//SA-β-gal activity assay//Western blot//BrdU Assay//Trypan blue staining |
| Pathway description: | When H460 lung carcinoma cells were treated with SP600125, cellular morphology, SA-β-Gal activity and colony-formation ability were compatible with senescence, indicating that this biological process was induced . Loss of phospho-Bcl-2 and phospho-pRB was also detected . Furthermore, ROS generation and DDR were observed along with a decrease in S-phase entry .HEFs transfected with siRNA of JNK or Bcl-2 exhibited SA-β-Gal activity and decreased cell numbers . |
Annotation:
Loading,please wait...